What makes a compliant Phase III and pre-launch patient advocacy strategy?
J Mark Access Health Policy
; 42016.
Article
em En
| MEDLINE
| ID: mdl-28003867
ABSTRACT
BACKGROUND:
A key task for the pharmaceutical industry is to understand the compliance implications of engaging with a patient advocacy group (PAG). This presents challenges for the industry to negotiate the ethical and reputational issues that can arise when working with a PAG.OBJECTIVE:
To gain the views of pharmaceutical industry executives on future compliance challenges when working with PAGs. STUDYDESIGN:
We conducted two surveys among two sets of industry executives one group focussed on market access roles and the other focussed on non-market access roles.RESULTS:
Transparency was identified as the biggest challenge, followed by project rationale and then by project ownership.CONCLUSION:
We explore how this can be overcome and make recommendations on how best to work compliantly with PAGs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article